| Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial R Stupp, S Taillibert, AA Kanner, W Read, DM Steinberg, B Lhermitte, ... Jama 318 (23), 2306-2316, 2017 | 2062 | 2017 |
| Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial R Stupp, S Taillibert, AA Kanner, S Kesari, DM Steinberg, SA Toms, ... Jama 314 (23), 2535-2543, 2015 | 1266 | 2015 |
| Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II … V Gondi, SL Pugh, WA Tome, C Caine, B Corn, AA Kanner, H Rowley, ... Journal of Clinical Oncology 32 (34), 3810, 2014 | 1097 | 2014 |
| NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality R Stupp, ET Wong, AA Kanner, D Steinberg, H Engelhard, V Heidecke, ... European journal of cancer 48 (14), 2192-2202, 2012 | 900 | 2012 |
| Serum S100β: A noninvasive marker of blood‐brain barrier function and brain lesions AA Kanner, N Marchi, V Fazio, MR Mayberg, MT Koltz, V Siomin, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 405 | 2003 |
| Peripheral markers of brain damage and blood-brain barrier dysfunction N Marchi, P Rasmussen, M Kapural, V Fazio, K Kight, MR Mayberg, ... Restorative neurology and neuroscience 21 (3, 4), 109-121, 2003 | 328 | 2003 |
| MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells H Gal, G Pandi, AA Kanner, Z Ram, G Lithwick-Yanai, N Amariglio, ... Biochemical and biophysical research communications 376 (1), 86-90, 2008 | 315 | 2008 |
| RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: phase 2 results S Ryu, SL Pugh, PC Gerszten, FF Yin, RD Timmerman, YJ Hitchcock, ... Practical radiation oncology 4 (2), 76-81, 2014 | 294 | 2014 |
| Intraoperative mapping and monitoring of the corticospinal tracts with neurophysiological assessment and 3-dimensional ultrasonography-based navigation E Nossek, A Korn, T Shahar, AA Kanner, H Yaffe, D Marcovici, ... Journal of neurosurgery 114 (3), 738-746, 2011 | 199 | 2011 |
| Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical … MJB Taphoorn, L Dirven, AA Kanner, G Lavy-Shahaf, U Weinberg, ... JAMA oncology 4 (4), 495-504, 2018 | 167 | 2018 |
| Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study S Constantini, A Kanner, A Friedman, Y Shoshan, Z Israel, E Ashkenazi, ... Journal of neurosurgery 94 (6), 918-921, 2001 | 111 | 2001 |
| Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician’s choice chemotherapy AA Kanner, ET Wong, JL Villano, Z Ram, EF-11 investigators Seminars in oncology 41, S25-S34, 2014 | 95 | 2014 |
| Delayed contrast extravasation MRI: a new paradigm in neuro-oncology L Zach, D Guez, D Last, D Daniels, Y Grober, O Nissim, C Hoffmann, ... Neuro-oncology 17 (3), 457-465, 2015 | 90 | 2015 |
| S100β as a predictor of brain metastases: brain versus cerebrovascular damage MA Vogelbaum, T Masaryk, P Mazzone, T Mekhail, V Fazio, S McCartney, ... Cancer 104 (4), 817-824, 2005 | 89 | 2005 |
| Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results A Chahlavi, A Kanner, D Peereboom, SM Staugaitis, P Elson, G Barnett Journal of neuro-oncology 61, 267-273, 2003 | 87 | 2003 |
| Intracranial navigation by using low-field intraoperative magnetic resonance imaging: preliminary experience AA Kanner, MA Vogelbaum, MR Mayberg, JP Weisenberger, GH Barnett Journal of neurosurgery 97 (5), 1115-1124, 2002 | 83 | 2002 |
| Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line? YR Lawrence, DT Blumenthal, D Matceyevsky, AA Kanner, F Bokstein, ... Journal of neuro-oncology 105, 1-7, 2011 | 76 | 2011 |
| NT-40 interim analysis of the EF-14 trial: a prospective, multi-center trial of NovoTTF-100A together with temozolomide compared to temozolomide alone in patients with newly … R Stupp, E Wong, C Scott, S Taillibert, A Kanner, S Kesari, Z Ram Neuro-oncology 16 (suppl_5), v167-v167, 2014 | 74 | 2014 |
| Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery VE Siomin, MA Vogelbaum, AA Kanner, SY Lee, JH Suh, GH Barnett Journal of neuro-oncology 67, 115-121, 2004 | 73 | 2004 |
| Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial S Kesari, R Stupp, ME Hegi, A Idbaih, DM Steinberg, AA Kanner, ... CNS oncology 6 (3), 185-193, 2017 | 62 | 2017 |
Gene BarnettCleveland ClinicVerified email at ccf.org
